RedHill Biopharma (RDHL) Other Non-Current Assets (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Other Non-Current Assets for 3 consecutive years, with $148000.0 as the latest value for Q4 2024.

  • Quarterly Other Non-Current Assets rose 0.68% to $148000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $148000.0 through Dec 2024, up 0.68% year-over-year, with the annual reading at $148000.0 for FY2024, 0.68% up from the prior year.
  • Other Non-Current Assets for Q4 2024 was $148000.0 at RedHill Biopharma, up from $147000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $150000.0 in Q4 2022, with the low at $147000.0 in Q4 2023.
  • Average Other Non-Current Assets over 3 years is $148333.3, with a median of $148000.0 recorded in 2024.
  • The sharpest move saw Other Non-Current Assets fell 2.0% in 2023, then rose 0.68% in 2024.
  • Over 3 years, Other Non-Current Assets stood at $150000.0 in 2022, then dropped by 2.0% to $147000.0 in 2023, then grew by 0.68% to $148000.0 in 2024.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $148000.0, $147000.0, and $150000.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.